OTCPK:RGBP - Post Discussion
Post by
MasterJedijazz on Oct 09, 2023 8:49am
$RGBP Undervalued PT $5 with $17M Market Cap
$RGBP Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months.
Our 6-12-month price target is $5.00. This target represents a $17.5 million market cap
https://www.goldmanresearch.com/202310041385/Opportunity-Research/an-emerging-cancer-and-autoimmune-player.html
Be the first to comment on this post